KRT18 and neoplasm: Thus, the kinetics of dulanermin-mediated caspase activation in the tumour parallel the appearance of cell-death markers (active caspase 3/7, cleaved CK18) in the serum and suggests that the circulating markers are tumour derived and occur in response to dulanermin treatment.